Selected article for: "aceis arbs and acute respiratory syndrome coronavirus"
Author: Vitiello, Antonio; Ferrara, Francesco
Title: Correlation between renin-angiotensin system and Severe Acute Respiratory Syndrome Coronavirus 2 infection: What do we know?
  • Cord-id: j501rt11
  • Document date: 2020_9_15
    • ID: j501rt11
    Snippet: The first cases of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2 or COVID-19) infections were recorded in China in November 2019. Since its appearance in China at the end of last year, the virus has spread to all continents causing a “global pandemic”. To date, some aspects remain to be investigate about the pathophysiology of this viral infection. One of the aspects to be still clarified is the correlation between the renin-angiotensin system (RAS) and SARS-CoV-2 infection. RA
    Document: The first cases of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2 or COVID-19) infections were recorded in China in November 2019. Since its appearance in China at the end of last year, the virus has spread to all continents causing a “global pandemic”. To date, some aspects remain to be investigate about the pathophysiology of this viral infection. One of the aspects to be still clarified is the correlation between the renin-angiotensin system (RAS) and SARS-CoV-2 infection. RAS is a physiological system playing a key role in different human body functions regulation. SARS-CoV-2 uses the angiotensin-converting enzyme 2 (ACE-2), a component of RAS, as a potential factor of cell penetration and infectivity; in addition, in the different infection stages, a functional variation of the RAS has been noted. In this article, we discuss the correlation between the role of RAS and system-modifying agents, angiotensin-converting enzyme inhibitors (ACEIs), angiotensin II receptor blockers (ARBs) and direct renin inhibitors (DRIs), with SARS-CoV-2 infection.

    Search related documents:
    Co phrase search for related documents
    • ace activity and lung injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
    • ace activity and lung tissue: 1, 2, 3, 4
    • ace angiotensin convert enzyme and acute respiratory syndrome: 1
    • ace concentration and acute respiratory syndrome: 1, 2, 3, 4, 5
    • ace concentration and lung injury: 1
    • ace concentration and lung tissue: 1
    • ace expression and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • ace expression and lung damage: 1
    • ace expression and lung include: 1
    • ace expression and lung injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23
    • ace expression and lung tissue: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
    • ace homology and acute respiratory syndrome: 1, 2, 3
    • ace homology and lung tissue: 1, 2
    • ace inhibition and acute respiratory syndrome: 1, 2, 3, 4, 5, 6
    • ace inhibition and lung injury: 1, 2, 3, 4
    • ace inhibition and lung tissue: 1, 2, 3
    • aceis enzyme inhibitor and acute respiratory syndrome: 1, 2
    • acute respiratory syndrome and liver release: 1, 2
    • acute respiratory syndrome and lung damage: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25